| Page 64 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Characterization of Myelodysplastic Syndromes (MDS) With T-cell Large Granular Lymphocyte Proliferations (LGL)

Author(s): 
Rami S Komrokji, Najla Al Ali, David Sallman, Eric Padron, Jeffrey Lancet, Lubomir Sokol, Christa Varnadoe, P K Burnette, Alan List
Primary Author: 
Rami S Komrokji
Journal Title: 
Leukemia
Original Publication Date: 
Jun 2020
Bone Marrow Disease(s): 

Immunomodulation With Pomalidomide at Early Lymphocyte Recovery After Induction Chemotherapy in Newly Diagnosed AML and High-Risk MDS

Author(s): 
Joshua F Zeidner, Hanna A Knaus, Amer M Zeidan, Amanda L Blackford, Raul Montiel-Esparza, Hubert Hackl, Gabrielle T Prince, Lukasz P Gondek, Gabriel Ghiaur, Margaret M Showel, Amy E DeZern, Keith W Pratz, B Douglas Smith
Primary Author: 
Joshua F Zeidner
Journal Title: 
Leukemia
Original Publication Date: 
Jun 2020

An immunosuppressive microenvironment promoting leukemia cell immune escape plays an important role in the pathogenesis of AML. Through its interaction with cereblon, a substrate receptor for the E3 ubiquitin ligase complex, pomalidomide leads to selective ubiquitination of transcription factors Aiolos and Ikaros thereby promoting immune modulation.

Bone Marrow Disease(s): 

MDS/MPN-RS-T Justified Inclusion as a Unique Disease Entity?

Author(s): 
Guillermo Montalban-Bravo, Guillermo Garcia-Manero
Primary Author: 
Guillermo Montalban-Bravo
Journal Title: 
Best practice & research. Clinical haematology
Original Publication Date: 
Jun 2020

Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) is a disease entity characterized by anemia,

Bone Marrow Disease(s): 

Therapy-related Myelodysplastic Syndromes Deserve Specific Diagnostic Sub-Classification and Risk-Stratification-An Approach to Classification of Patients With t-MDS

Author(s): 
A Kuendgen, M Nomdedeu, H Tuechler, G Garcia-Manero, R S Komrokji, M A Sekeres, M G Della Porta, M Cazzola, A E DeZern, G J Roboz, D P Steensma, A A Van de Loosdrecht, R F Schlenk, J Grau, X Calvo, S Blum
Primary Author: 
A Kuendgen
Journal Title: 
Leukemia
Original Publication Date: 
Jun 2020

In the current World Health Organization (WHO)-classification, therapy-related

Bone Marrow Disease(s): 

Cyclosporine Enhances the Sensitivity to Lenalidomide in MDS/AML in Vitro

Author(s): 
Xiaofei He, Aixia Dou, Saran Feng, Ashley Roman-Rivera, Caleb Hawkins, Lauren Lawley, Jiajia Zhang, Mark Wunderlich, Benjamin Mizukawa, Stephanie Halene, Amisha Patel, Jing Fang
Primary Author: 
Xiaofei He
Journal Title: 
Experimental Hematology
Original Publication Date: 
Jun 2020

Our previous study revealed that expression of G protein-coupled receptor 68 (GPR68) was upregulated in MDSL cells, a cell line representing

Bone Marrow Disease(s): 

Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry

Author(s): 
Hubert Schrezenmeier, Alexander Röth, David J Araten, Yuzuru Kanakura, Loree Larratt, Jamile M Shammo, Amanda Wilson, Gilda Shayan, Jaroslaw P Maciejewski
Primary Author: 
Hubert Schrezenmeier
Journal Title: 
Annals of Hematology
Original Publication Date: 
Jul 2020

The International

Bone Marrow Disease(s):